caa a22 4500 605490295 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0685-3 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0685-3 Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases [Elektronische Daten] [Yoshitsugu Shibayama, Shinichi Imafuku, Akira Takahashi, Juichiro Nakayama] Background: Merkel cell carcinoma (MCC) is a rare cutaneous malignancy with a high rate of nodal metastasis. Sentinel lymph node biopsy (SLNB) is used in MCC and other cancers to identify regional node micrometastases in patients with clinically negative nodes; however, whether SLN status is associated with recurrence or prognosis in MCC is unclear. Methods: A statistical analysis was performed of 397 published cases of MCC with SLNB results from 22 reports and 6 new cases, in order to elucidate any correlation between SLN status and recurrence, and to determine false-negative rates for SLNB. Results: Of these 403 cases, 128 (31.8%) had positive SLNs; 16 of these 128 (12.5%) developed recurrence (6 nodal, 10 distant). Of 275 patients with negative SLNs, 27 (9.8%) developed recurrence (19 nodal, 8 distant). Patients with positive SLNs had a greater risk of distant metastasis (OR 2.82; P=0.037; 95% CI 1.089-7.347). The false-negative rate for SLNB in all 403 patients was 12.9%. Use of the immunohistochemical approach to diagnosis of micrometastasis with anti-CK20 antibody did not affect the false-negative rate. Conclusions: Patients with positive SLNs had a greater risk of distant metastasis in MCC; positive SLN was an important prognostic factor in MCC. Further studies using standardized, more-sensitive techniques to examine entire SLNs may decrease the false-negative rate, and improve the significance of SLNB in MCC. Japan Society of Clinical Oncology, 2014 Merkel cell carcinoma nationallicence Sentinel lymph node nationallicence False negative nationallicence Recurrence nationallicence Meta-analysis nationallicence Shibayama Yoshitsugu Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut Imafuku Shinichi Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut Takahashi Akira Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut Nakayama Juichiro Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 188-193 1341-9625 20:1<188 2015 20 10147 https://doi.org/10.1007/s10147-014-0685-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0685-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Shibayama Yoshitsugu Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut NATIONALLICENCE 700 1- Imafuku Shinichi Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut NATIONALLICENCE 700 1- Takahashi Akira Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut NATIONALLICENCE 700 1- Nakayama Juichiro Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, 814-0133, Fukuoka, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 188-193 1341-9625 20:1<188 2015 20 10147